About Vaxcyte
Vaxcyte is a company based in Foster City (United States) founded in 2013 by Jeff Fairman. Vaxcyte has raised $347 million across 8 funding rounds from investors including TPG, HHS and Janus Henderson Investors. The company has 414 employees as of December 31, 2024. Vaxcyte offers products and services including VAX-31 and VAX-24. Vaxcyte operates in a competitive market with competitors including Biological E, Vir Biotechnology, Cidara Therapeutics, Freeline and Valneva, among others.
- Headquarter Foster City, United States
- Employees 414 as on 31 Dec, 2024
- Founders Jeff Fairman
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vaxcyte, Inc.
-
Annual Revenue
-
Net Profit
-$463.93 M (USD)-15.33as on Dec 31, 2024
-
EBITDA
-$553.7 M (USD)-44.62as on Dec 31, 2024
-
Total Equity Funding
$347 M (USD)
in 8 rounds
-
Latest Funding Round
$110 M (USD), Series D
Apr 03, 2020
-
Investors
TPG
& 12 more
-
Employee Count
414
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Vaxcyte
Vaxcyte is a publicly listed company on the NASDAQ with ticker symbol PCVX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Vaxcyte
Vaxcyte offers a comprehensive portfolio of products and services, including VAX-31 and VAX-24.
Vaccine designed to prevent invasive pneumococcal disease in children and adults.
Vaccine for protection against pneumococcal infections through advanced immunogenicity.
People of Vaxcyte
Unlock access to complete
Unlock access to complete
Leadership Team
45 people
Software Development Team
38 people
Product Management Team
24 people
Senior Team
23 people
Human Resources and Administration
8 people
Operations Team
7 people
Scientific Team
7 people
Finance and Accounting
6 people
Unlock access to complete
Funding Insights of Vaxcyte
Vaxcyte has successfully raised a total of $347M across 8 strategic funding rounds. The most recent funding activity was a Series D round of $110 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series D — $110.0M
-
First Round
First Round
(01 Dec 2013)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2020 | Amount | Series D - Vaxcyte | Valuation | RA Capital Management , Janus Henderson Investors | |
| Sep, 2019 | Amount | Grant - Vaxcyte | Valuation |
investors |
|
| Jun, 2018 | Amount | Series C - Vaxcyte | Valuation | TPG |
Investors in Vaxcyte
Vaxcyte has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include TPG, HHS and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location | |
|
Private equity firm focused on life science sector
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vaxcyte
Financial Statements - Vaxcyte
Vaxcyte Comparisons
Competitors of Vaxcyte
Vaxcyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Vir Biotechnology, Cidara Therapeutics, Freeline and Valneva, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
|
| domain | founded_year | HQ Location |
Prophylactic vaccines for infectious diseases are developed and advanced.
|
Frequently Asked Questions about Vaxcyte
Vaxcyte was founded in 2013.
Vaxcyte is headquartered in Foster City, United States. It is registered at Foster City, California, United States.
Vaxcyte is a funded company, having raised a total of $347M across 8 funding rounds to date. The company's 1st funding round was a Series C of $85M, raised on Dec 01, 2013.
As of Dec 31, 2024, the latest employee count at Vaxcyte is 414.
Vaxcyte was founded in 2013 in Foster City, United States, within the biotechnology sector. Focus is placed on developing vaccines against infectious diseases through the XpressCF platform and proprietary knowledge for protein carriers and antigens. Site-specific conjugation is employed to create building blocks for pneumococcal conjugate vaccines like VAS-24. Efforts target invasive pneumococcal diseases, otitis media, strep infections, and periodontitis.
Vaxcyte's top competitors include Serum Institute of India, Biological E and RedHill Biopharma.
Vaxcyte offers VAX-31 and VAX-24.
Yes, Vaxcyte is publicly traded on NASDAQ under the ticker symbol PCVX.
Vaxcyte has 13 investors. Key investors include TPG, HHS, Janus Henderson Investors, RA Capital, and CARB-X.
The ticker symbol of Vaxcyte is PCVX on NASDAQ.